- Home
- SKT vs ACLX Comparison
SKT vs ACLX Comparison
Compare SKT & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | ACLX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1993 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SKT | ACLX |
|---|---|---|
| Price | $34.06 | $62.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $36.00 | ★ $115.71 |
| AVG Volume (30 Days) | 766.1K | ★ 1.1M |
| Earning Date | 02-24-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $575,140,000.00 | $35,898,000.00 |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $4.62 | $293.08 |
| P/E Ratio | $35.48 | ★ N/A |
| Revenue Growth | ★ 10.01 | N/A |
| 52 Week Low | $28.69 | $47.86 |
| 52 Week High | $36.76 | $94.07 |
Technical Indicators
Market Signals| Indicator | SKT | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 33.55 |
| Support Level | $32.81 | $60.36 |
| Resistance Level | $34.11 | $65.97 |
| Average True Range (ATR) | 0.53 | 2.12 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 67.02 | 22.42 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owners and operators of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers, with a total gross leasable area of approximately 13.0 million square feet.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.